How are MNKD strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MNKD strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 35.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$17.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a MNKD strangle?

The breakeven for the MNKD strangle priced on this page is roughly $3.33 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The MNKD market-implied 1-standard-deviation expected move in the same options snapshot is approximately 10.24%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current MNKD implied volatility affect this strangle?

MNKD ATM IV is at 35.70% with IV rank near 6.29%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

MNKD Strangle Strategy

MNKD (MannKind Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes.

MNKD (MannKind Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.23B, a beta of 1.10 versus the broader market, a 52-week range of 2.23-6.51, average daily share volume of 5.3M, a public-listing history dating back to 2004, approximately 592 full-time employees. These structural characteristics shape how MNKD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.10 places MNKD roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on MNKD?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

MNKD snapshot

As of August 14, 2026, spot at $3.83, ATM IV 35.70%, IV rank 6.29%, expected move 10.24%. The strangle on MNKD below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 7-day expiry.

Why this strangle structure on MNKD specifically: MNKD IV at 35.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a MNKD strangle, with a market-implied 1-standard-deviation move of approximately 10.24% (roughly $0.39 on the underlying). The 7-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MNKD expiries trade a higher absolute premium for lower per-day decay. Position sizing on MNKD should anchor to the underlying notional of $3.83 per share and to the trader's directional view on MNKD stock.

MNKD strangle setup

The MNKD strangle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MNKD at $3.83 on that close, the first option leg uses a $4.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MNKD chain at a 7-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MNKD shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$4.00	$0.10
Buy 1	Put	$3.50	$0.07

MNKD strangle risk and reward

Net Premium / Debit: -$17.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$17.00
Breakeven(s): $3.33
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

MNKD strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on MNKD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.7%	+$332.00
$0.86	-77.7%	+$247.43
$1.70	-55.6%	+$162.85
$2.55	-33.5%	+$78.28
$3.39	-11.4%	-$6.29
$4.24	+10.7%	+$6.86
$5.08	+32.8%	+$91.44
$5.93	+54.8%	+$176.01
$6.78	+76.9%	+$260.58
$7.62	+99.0%	+$345.16

When traders use strangle on MNKD

Strangles on MNKD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MNKD chain.

MNKD thesis for this strangle

The market-implied 1-standard-deviation range for MNKD extends from approximately $3.44 on the downside to $4.22 on the upside. A MNKD long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current MNKD IV rank near 6.29% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on MNKD at 35.70%. As a Healthcare name, MNKD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MNKD-specific events.

MNKD strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MNKD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MNKD alongside the broader basket even when MNKD-specific fundamentals are unchanged. Always rebuild the position from current MNKD chain quotes before placing a trade.

Frequently asked questions

What is a strangle on MNKD?: A strangle on MNKD is the strangle strategy applied to MNKD (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With MNKD stock at $3.83 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed MNKD chain strike and the premiums come straight from that session's bid/ask midpoint.
How are MNKD strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MNKD strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 35.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$17.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a MNKD strangle?: The breakeven for the MNKD strangle priced on this page is roughly $3.33 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The MNKD market-implied 1-standard-deviation expected move in the same options snapshot is approximately 10.24%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on MNKD?: Strangles on MNKD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MNKD chain.
How does current MNKD implied volatility affect this strangle?: MNKD ATM IV is at 35.70% with IV rank near 6.29%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.